For Investors

Arquer Diagnostics is a UK-based company committed to manufacturing and marketing innovative, non-invasive tests for diagnosing and monitoring cancer.

Its first product, ADXBLADDER, is a game-changing urine test to diagnose new tumours in patients showing symptoms and to monitor for recurrent tumours in patients with a history of bladder cancer.

Its rigorous clinical trials show unequivocally that its test is quicker and more accurate than the current standard diagnostic journey.

Arquer’s approach and tests are supported by highly regarded expert KOLs at leading international organisations: University Hospital Southampton and Sunderland Royal Hospital in the UK; Pitié Salpêtrière University Hospital and Hôpital Edouard Herriot, Lyon in France; University Hospital Fundació Puigvert in Spain; Radboud University Medical Centre, Nijmegen in The Netherlands; as well as Ospedale Molinette, Turin, and Universita’Policlinico Milano, in Italy.

The breakthrough technology is also showing positive early data in the diagnosis of prostate and endometrial cancers and similar products are undergoing clinical validations.

The test uses standard ELISA methods, available in almost every hospital laboratory, requires only 10mls of urine and takes just three hours to achieve a “yes/no” result.